H. Lundbeck Valuation
Is HLUN B undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of HLUN B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: HLUN B (DKK43.58) is trading below our estimate of fair value (DKK194.31)
Significantly Below Fair Value: HLUN B is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for HLUN B?
Other financial metrics that can be useful for relative valuation.
What is HLUN B's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | DKK 42.22b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 2x |
Enterprise Value/EBITDA | 7.7x |
PEG Ratio | 1.8x |
Price to Earnings Ratio vs Peers
How does HLUN B's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 37.6x | ||
ALK B ALK-Abelló | 64.3x | 19.5% | DKK 35.7b |
NOVO B Novo Nordisk | 44.8x | 14.4% | DKK 4.0t |
GMAB Genmab | 20.9x | 21.1% | DKK 115.6b |
HIK Hikma Pharmaceuticals | 20.6x | 12.2% | UK£4.5b |
HLUN B H. Lundbeck | 17.9x | 9.8% | DKK 42.2b |
Price-To-Earnings vs Peers: HLUN B is good value based on its Price-To-Earnings Ratio (17.9x) compared to the peer average (37.6x).
Price to Earnings Ratio vs Industry
How does HLUN B's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?
Price-To-Earnings vs Industry: HLUN B is good value based on its Price-To-Earnings Ratio (17.9x) compared to the European Pharmaceuticals industry average (23.8x).
Price to Earnings Ratio vs Fair Ratio
What is HLUN B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 17.9x |
Fair PE Ratio | 24.7x |
Price-To-Earnings vs Fair Ratio: HLUN B is good value based on its Price-To-Earnings Ratio (17.9x) compared to the estimated Fair Price-To-Earnings Ratio (24.7x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | DKK 43.58 | DKK 41.96 -3.7% | 14.2% | DKK 55.00 | DKK 35.00 | n/a | 12 |
Aug ’25 | DKK 43.52 | DKK 40.88 -6.1% | 12.5% | DKK 55.00 | DKK 35.00 | n/a | 12 |
Jul ’25 | DKK 38.60 | DKK 39.96 +3.5% | 10.9% | DKK 51.00 | DKK 35.00 | n/a | 12 |
Jun ’25 | DKK 37.74 | DKK 39.96 +5.9% | 10.9% | DKK 51.00 | DKK 35.00 | n/a | 12 |
May ’25 | DKK 34.04 | DKK 38.71 +13.7% | 12.3% | DKK 50.00 | DKK 33.00 | n/a | 12 |
Apr ’25 | DKK 33.22 | DKK 38.79 +16.8% | 12.2% | DKK 50.00 | DKK 33.00 | n/a | 12 |
Mar ’25 | DKK 33.06 | DKK 38.35 +16.0% | 12.5% | DKK 50.00 | DKK 33.00 | n/a | 13 |
Feb ’25 | DKK 34.00 | DKK 38.27 +12.6% | 11.0% | DKK 48.00 | DKK 33.00 | n/a | 13 |
Jan ’25 | DKK 32.76 | DKK 38.58 +17.8% | 10.4% | DKK 48.00 | DKK 33.00 | n/a | 13 |
Dec ’24 | DKK 33.06 | DKK 38.79 +17.3% | 10.8% | DKK 48.00 | DKK 32.00 | n/a | 12 |
Nov ’24 | DKK 37.16 | DKK 39.05 +5.1% | 11.1% | DKK 47.00 | DKK 32.00 | n/a | 11 |
Oct ’24 | DKK 38.10 | DKK 37.77 -0.9% | 11.0% | DKK 47.00 | DKK 32.00 | n/a | 11 |
Sep ’24 | DKK 35.20 | DKK 37.38 +6.2% | 12.0% | DKK 47.00 | DKK 30.00 | n/a | 12 |
Aug ’24 | DKK 33.78 | DKK 37.13 +9.9% | 10.8% | DKK 44.00 | DKK 30.00 | DKK 43.52 | 12 |
Jul ’24 | DKK 32.44 | DKK 36.88 +13.7% | 12.5% | DKK 44.00 | DKK 30.00 | DKK 38.60 | 12 |
Jun ’24 | DKK 36.84 | DKK 36.88 +0.1% | 12.5% | DKK 44.00 | DKK 30.00 | DKK 37.74 | 12 |
May ’24 | DKK 35.70 | DKK 34.63 -3.0% | 15.6% | DKK 44.00 | DKK 30.00 | DKK 34.04 | 12 |
Apr ’24 | DKK 31.78 | DKK 33.71 +6.1% | 14.3% | DKK 42.50 | DKK 27.00 | DKK 33.22 | 12 |
Mar ’24 | DKK 29.77 | DKK 33.42 +12.3% | 14.2% | DKK 42.50 | DKK 27.00 | DKK 33.06 | 13 |
Feb ’24 | DKK 25.38 | DKK 33.19 +30.8% | 15.2% | DKK 43.00 | DKK 27.00 | DKK 34.00 | 13 |
Jan ’24 | DKK 26.05 | DKK 35.27 +35.4% | 18.6% | DKK 46.00 | DKK 27.00 | DKK 32.76 | 13 |
Dec ’23 | DKK 26.36 | DKK 36.19 +37.3% | 16.7% | DKK 46.00 | DKK 27.00 | DKK 33.06 | 13 |
Nov ’23 | DKK 27.95 | DKK 37.65 +34.7% | 15.5% | DKK 46.00 | DKK 27.00 | DKK 37.16 | 13 |
Oct ’23 | DKK 24.32 | DKK 39.27 +61.5% | 11.8% | DKK 46.00 | DKK 31.00 | DKK 38.10 | 13 |
Sep ’23 | DKK 28.32 | DKK 39.89 +40.9% | 11.6% | DKK 46.00 | DKK 32.60 | DKK 35.20 | 13 |
Aug ’23 | DKK 35.95 | DKK 41.05 +14.2% | 13.8% | DKK 54.00 | DKK 32.60 | DKK 33.78 | 13 |
Analyst Forecast: Target price is lower than the current share price.